Stock KOPRAN KOPRAN LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Kopran Limited

Equities

KOPRAN

INE082A01010

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 11:00:49 29/04/2024 BST 		5-day change 1st Jan Change
264.2 INR +3.63% Intraday chart for Kopran Limited +2.62% +9.42%
02-07 Kopran Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
2023 Kopran Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 2,385 1,799 1,096 4,539 13,574 5,325
Enterprise Value (EV) 1 3,269 2,764 1,971 5,193 14,261 6,003
P/E ratio 11.6 x 7.5 x 5.22 x 7.37 x 20.4 x 19.6 x
Yield - - - 2.86% 1.07% 2.72%
Capitalization / Revenue 0.76 x 0.5 x 0.3 x 0.92 x 2.84 x 0.97 x
EV / Revenue 1.04 x 0.77 x 0.55 x 1.06 x 2.99 x 1.09 x
EV / EBITDA 10.7 x 5.96 x 4.14 x 6.33 x 16.3 x 10.5 x
EV / FCF -82.4 x -17.3 x 11 x 87 x -10.3 x 32.8 x
FCF Yield -1.21% -5.77% 9.08% 1.15% -9.7% 3.05%
Price to Book 1.65 x 1.07 x 0.58 x 1.85 x 3.19 x 1.21 x
Nbr of stocks (in thousands) 43,253 43,253 43,253 43,251 48,213 48,211
Reference price 2 55.15 41.60 25.35 105.0 281.6 110.4
Announcement Date 29/05/18 28/06/19 24/08/20 02/08/21 06/08/22 25/05/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 3,147 3,579 3,595 4,918 4,775 5,510
EBITDA 1 305.5 463.9 475.9 820.1 872.9 572.5
EBIT 1 220.6 376.7 380.4 724.1 769.2 452.8
Operating Margin 7.01% 10.52% 10.58% 14.72% 16.11% 8.22%
Earnings before Tax (EBT) 1 228.9 316.6 282.8 833.4 817.8 360.7
Net income 1 204.9 240.2 210.2 616.1 610.3 272.3
Net margin 6.51% 6.71% 5.85% 12.53% 12.78% 4.94%
EPS 2 4.736 5.550 4.860 14.24 13.77 5.649
Free Cash Flow 1 -39.68 -159.5 178.9 59.69 -1,383 183.2
FCF margin -1.26% -4.46% 4.98% 1.21% -28.96% 3.33%
FCF Conversion (EBITDA) - - 37.59% 7.28% - 32.01%
FCF Conversion (Net income) - - 85.1% 9.69% - 67.28%
Dividend per Share - - - 3.000 3.000 3.000
Announcement Date 29/05/18 28/06/19 24/08/20 02/08/21 06/08/22 25/05/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 884 965 874 654 687 678
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 2.894 x 2.081 x 1.837 x 0.7971 x 0.7868 x 1.185 x
Free Cash Flow 1 -39.7 -160 179 59.7 -1,383 183
ROE (net income / shareholders' equity) 15.2% 15.3% 11.7% 28.3% 18.2% 6.29%
ROA (Net income/ Total Assets) 4.49% 7.05% 6.57% 11.2% 9.15% 4.49%
Assets 1 4,560 3,407 3,199 5,519 6,667 6,065
Book Value Per Share 2 33.50 39.00 43.90 56.70 88.40 91.10
Cash Flow per Share 2 0.1000 0.1000 0.1900 0.2200 1.220 1.530
Capex 1 105 276 - 236 398 549
Capex / Sales 3.34% 7.71% - 4.8% 8.32% 9.96%
Announcement Date 29/05/18 28/06/19 24/08/20 02/08/21 06/08/22 25/05/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
KOPRAN LIMITED Stock Kopran Limited
+9.42% 147M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.97% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.74% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.59% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.70% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.62% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.43% 231B
NOVARTIS AG Stock Novartis AG
+4.71% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.53% 195B
AMGEN INC. Stock Amgen Inc.
-4.30% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. KOPRAN Stock
  4. Financials Kopran Limited